Citigroup
EDIT icon

Citigroup’s Editas Medicine EDIT Stock Holding History

Citigroup’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$18K Buy
7,298
+2,261
+45% +$4.79K ﹤0.01% 4864
2025
Q4 		$10.3K Sell
5,037
-3,322
-40% -$9.59K ﹤0.01% 5046
2025
Q3 		$29K Sell
8,359
-51,526
-86% -$144K ﹤0.01% 4678
2025
Q2 		$132K Sell
59,885
-3,272
-5% -$5.35K ﹤0.01% 4280
2025
Q1 		$73.3K Sell
63,157
-35,946
-36% -$52.9K ﹤0.01% 4756
2024
Q4 		$126K Buy
99,103
+33,368
+51% +$85K ﹤0.01% 4716
2024
Q3 		$224K Sell
65,735
-118
-0.2% -$514 ﹤0.01% 4261
2024
Q2 		$308K Sell
65,853
-626,080
-90% -$3.53M ﹤0.01% 3675
2024
Q1 		$5.13M Buy
691,933
+541,839
+361% +$4.5M ﹤0.01% 1688
2023
Q4 		$1.52M Sell
150,094
-62,488
-29% -$549K ﹤0.01% 2479
2023
Q3 		$1.66M Buy
212,582
+25,532
+14% +$219K ﹤0.01% 2123
2023
Q2 		$1.54M Sell
187,050
-445,421
-70% -$3.88M ﹤0.01% 2462
2023
Q1 		$4.59M Buy
632,471
+286,589
+83% +$2.55M ﹤0.01% 1549
2022
Q4 		$3.07M Sell
345,882
-81,816
-19% -$898K ﹤0.01% 1754
2022
Q3 		$5.24M Sell
427,698
-60,569
-12% -$944K ﹤0.01% 1541
2022
Q2 		$5.78M Buy
488,267
+405,097
+487% +$5.43M ﹤0.01% 1456
2022
Q1 		$1.58M Sell
83,170
-100,275
-55% -$1.86M ﹤0.01% 2547
2021
Q4 		$4.87M Buy
183,445
+113,444
+162% +$3.9M ﹤0.01% 1853
2021
Q3 		$2.88M Sell
70,001
-73,365
-51% -$4.02M ﹤0.01% 2237
2021
Q2 		$8.12M Buy
143,366
+33,485
+30% +$1.24M ﹤0.01% 1559
2021
Q1 		$4.62M Buy
109,881
+69,228
+170% +$3.94M ﹤0.01% 1838
2020
Q4 		$2.85M Sell
40,653
-28,071
-41% -$1.15M ﹤0.01% 2523
2020
Q3 		$1.93M Sell
68,724
-48,362
-41% -$1.58M ﹤0.01% 2685
2020
Q2 		$3.46M Sell
117,086
-36,923
-24% -$965K ﹤0.01% 2219
2020
Q1 		$3.05M Buy
154,009
+86,412
+128% +$2.18M ﹤0.01% 2087
2019
Q4 		$2M Sell
67,597
-29,171
-30% -$729K ﹤0.01% 2975
2019
Q3 		$2.2M Buy
96,768
+42,997
+80% +$1.07M ﹤0.01% 2757
2019
Q2 		$1.33M Sell
53,771
-943
-2% -$22.5K ﹤0.01% 3298
2019
Q1 		$1.34M Sell
54,714
-151,255
-73% -$3.42M ﹤0.01% 3075
2018
Q4 		$4.69M Buy
205,969
+165,930
+414% +$4.52M ﹤0.01% 1865
2018
Q3 		$1.27M Sell
40,039
-38,686
-49% -$1.25M ﹤0.01% 3212
2018
Q2 		$2.82M Buy
78,725
+10,367
+15% +$367K ﹤0.01% 2385
2018
Q1 		$2.27M Sell
68,358
-32,717
-32% -$1.17M ﹤0.01% 2497
2017
Q4 		$3.11M Buy
101,075
+55,794
+123% +$1.4M ﹤0.01% 2263
2017
Q3 		$1.09M Buy
45,281
+45,008
+16,486% +$857K ﹤0.01% 3277
2017
Q2 		$5K Buy
273
+96
+54% +$1.73K ﹤0.01% 6734
2017
Q1 		$4K Sell
177
-9,192
-98% -$190K ﹤0.01% 6854
2016
Q4 		$152K Buy
9,369
+8,758
+1,433% +$133K ﹤0.01% 5506
2016
Q3 		$8K Sell
611
-127
-17% -$2.6K ﹤0.01% 6618
2016
Q2 		$18K Sell
738
-4,948
-87% -$167K ﹤0.01% 6219
2016
Q1 		$196K Buy
+5,686
New +$149K ﹤0.01% 5110

Other funds holding EDIT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Citigroup's EDIT Position: Q1 2026 in Review

Citigroup increased its Editas Medicine (EDIT) stake by 45% in Q1 2026, buying an estimated $4.79K and bringing the position to 7,298 shares worth $18K. The position accounts for ﹤0.01% of the portfolio, ranked #4864.

Citigroup first reported a position in EDIT in Q1 2016 and has held it in 41 quarters since. The position peaked at $8.12M in Q2 2021. 207 funds tracked by Wall St. Rank hold EDIT as of Q1 2026.

  • Citigroup held 7,298 shares of Editas Medicine worth $18K as of Q1 2026.
  • Citigroup bought 2,261 Editas Medicine shares in Q1 2026, an estimated $4.79K.
  • Editas Medicine made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #4864 holding.
  • Citigroup first reported a position in Editas Medicine in Q1 2016 and has held it in 41 quarters since.
  • Citigroup's Editas Medicine position peaked at $8.12M in Q2 2021.
  • 207 funds tracked by Wall St. Rank held Editas Medicine as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.